GIP
CYTK icon

Granite Investment Partners’s Cytokinetics CYTK Stock Holding History

Granite Investment Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-39,732
Closed -$576K – 304
2017
Q3 		$576K Buy
+39,732
New +$543K 0.04% 257

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Granite Investment Partners's CYTK Position: Q4 2017 in Review

Granite Investment Partners sold out of Cytokinetics (CYTK) in Q4 2017, closing a stake of 39,732 shares — an estimated $576K sold.

Granite Investment Partners first reported a position in CYTK in Q3 2017 and held it in 1 quarter. The position peaked at $576K in Q3 2017. 134 funds tracked by Wall St. Rank hold CYTK as of Q4 2017.

  • Granite Investment Partners reported no remaining Cytokinetics position as of Q4 2017 after selling out during the quarter.
  • Granite Investment Partners sold 39,732 Cytokinetics shares in Q4 2017, an estimated $576K.
  • Granite Investment Partners first reported a position in Cytokinetics in Q3 2017 and held it in 1 quarter.
  • Granite Investment Partners's Cytokinetics position peaked at $576K in Q3 2017.
  • 134 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2017.

Based on Granite Investment Partners's 13F filing for Q4 2017, filed 1 Feb 2018.